- France criticises being left on England’s ‘amber plus’ list
- Once a Covid success story, South Korea sweats through summer of Delta surge
- Five Cuban generals dead in recent days – is the Covid spike to blame?
- UK Covid updates – live
- See all our coronavirus coverage
The US health regulator has expanded the emergency use authorization for Eli Lilly’s Covid-19 drug baricitinib, saying it could now be used without taking Gilead’s drug remdesivir along with it, Lilly has said.
In November, the US Food and Drug Administration (FDA) approved Lilly and Incyte’s arthritis drug, baricitinib, in combination with remdesivir, to treat Covid-19 patients.
The world is witnessing the emergence of more infectious variants of the Sars-CoV-2 virus, write several World Health Organization envoys, but a stuttering race to ensure equitable access to vaccines has seen a handful of countries streak ahead, immunising their own populations, leaving many of the world’s vulnerable people in their wake.
Countries with the greatest stocks of vaccines should not hoard them and push to cover their entire populations while other countries do without. It is not even in their best interests, since the intense circulation of the virus in countries with no vaccines increases the possibility of more transmissible and dangerous variants, threatening to make current vaccines less effective.
Read the original article at The Guardian